Objectives: The purpose of this study was to describe a putative role for a novel soxS mutation in contributing to multiple-antibiotic resistance in canine fluoroquinolone-associated MDR (FQ-MDR) Escherichia coli. This soxS mutation was discovered in canine faecal E. coli isolates during a study investigating the effect of oral fluoroquinolone administration on faecal E. coli in healthy dogs.
Introduction
Fluoroquinolone (FQ) resistance has been reported among different members of the family Enterobacteriaceae including Escherichia coli. 1,2 High-level FQ resistance is also associated with multidrug resistance. 3, 4 Recently, multidrug resistance has been linked to FQ resistance through mutations within the regulatory loci that control the expression of the AcrAB efflux pump. 3, 5 AcrAB-TolC is one of the most common efflux pumps associated with antimicrobial resistance in E. coli and has a wide substrate specificity to render the organism simultaneously resistant to many antibiotics. 6 The expression of the acrAB operon is regulated locally by AcrR and AcrS, 7 while globally it is influenced by several transcriptional activators belonging to the AraC/XylS family, especially MarA and SoxS. 8 The SoxS protein is a transcription factor that activates the expression of more than 100 genes in the chromosomally encoded SoxRS regulon. 9 In E. coli, SoxR is constitutively expressed and binds to its sole DNA target, a site in the promoter of the soxS gene, without activating its transcription. 8 When exposed to oxidative stress, the SoxR protein activates the transcription of soxS, 10 which in turn results in an overexpression of the target genes including acrAB. 6, 7 In both laboratory and clinical strains of E. coli, activation of the soxRS regulon has been shown to contribute to the increased resistance to quinolones and chloramphenicol. 11 However, few data exist regarding mutations in soxS and their importance in the acquisition of FQ resistance. We previously demonstrated that the administration of enrofloxacin to dogs in low therapeutic doses was associated with the emergence of FQ-associated MDR (FQ-MDR) faecal E. coli isolates that contained a novel soxS mutation. 3 The same soxS mutation has been encountered in clinical FQ-MDR E. coli isolates from the urine of dogs with a suspected urinary tract infection. this study was to describe a putative new role for a novel soxS mutation in the contribution to multiple-antibiotic resistance in canine FQ-MDR E. coli.
Materials and methods
Bacterial isolates (Table 1) Experimental E. coli isolates Three faecal FQ-MDR E. coli isolates harbouring the soxS A12S mutation were detected during an investigation of the effect of oral FQ administration on canine faecal E. coli. The three isolates contained two mutations in gyrA and two mutations in parC and belonged to three different PFGE pulsotypes. 5 Phylogenetic analysis showed that two E. coli isolates belonged to the B1 phylotype (S61 and S71) and one E. coli isolate belonged to the D phylotype (S81).
Clinical E. coli isolates
FQ-MDR clinical E. coli isolates containing the soxS A12S mutation (n ¼ 3) were drawn from a larger study investigating the mechanisms of FQ-multidrug resistance in companion animals. The three E. coli isolates harboured two mutations in gyrA, a single mutation in gyrB and two mutations in parC and belonged to the B1 phylotype. 6 Sequencing of soxS, soxR and marR from E. coli isolates E. coli isolates were tested for mutations in genes encoding regulators of the AcrAB efflux pump (soxR, soxS and marR) by PCR and DNA sequencing. The primers that were used are listed in Table S1 (available as Supplementary data at JAC Online).
RNA extraction and relative quantification of gene expression by quantitative real-time RT-PCR (RT-qPCR)
FQ-MDR E. coli isolates were examined by RT -qPCR for the mRNA expression of genes encoding for efflux pump AcrB and its regulators (SoxS and MarA). Overnight bacterial cultures were diluted 1/100 in fresh LB broth and grown with shaking (250 rpm) for 90 min at 378C. At this point, the cultures were divided and the appropriate samples were treated with 250 mM paraquat (PQ), a redox-cycling agent and inducer of the soxRS regulon. PQ-treated cells were further incubated at 378C for another 30 min. RNA was extracted as previously described. 6 Reverse transcription of RNA into cDNA was carried out using the iScript Reverse Transcription kit (Bio-Rad, USA). The quantification of cDNA templates by RT -qPCR was performed in a Roche LightCycler 480 using a Roche SYBR Green RT -PCR kit (Roche, USA). The expression of each gene was normalized to that of a ribosomal housekeeping gene (gapA). The relative expression of each target gene was calibrated against the corresponding expression by E. coli ATCC 25922 (expression ¼ 1), which served as the control.
Cloning of mutant soxS from E. coli isolates
A 870 bp fragment corresponding to the soxS region (the soxS gene and its promoter) of the WT soxS and soxS A12S was amplified by PCR from the genomic DNA of the E. coli isolates (from both WT E. coli and resistant E. coli). The amplified fragments were cloned into vector pCR2.1 (Ap r , Kn r ) using the pCR2.1 TA cloning kit (Invitrogen, Carlsbad, USA) to generate two plasmids, pSAWT (WT soxS) and pSAMT (soxS A12S ).The clones were confirmed by restriction digestion analysis with EcoRI and BamHI and DNA sequencing.
Complementation of a DsoxS strain with cloned soxS alleles for increased antibiotic resistance
The pSAWT and pSAMT plasmids were introduced into E. coli K-12: JW4023 (soxS::kn, DlacZ), producing strains DB0002 and DB0003, respectively, and their contribution to the antibiotic resistance phenotype of the recipient strain was assessed by Etest. As a control, the E. coli carrying the vector plasmid alone was also subjected to the Etest. The antibiotics tested were enrofloxacin, ciprofloxacin, doxycycline and chloramphenicol.
Reconstruction of the soxS A12S mutation in the E. coli JW4023 strain (soxS::kn, DlacZ)
The soxS A12S mutant allele was inserted into the chromosome via allelic exchange with the soxS::kn insertion allele using the negative selection marker sacB. Plasmid pGP704, an R6K derivative that can be maintained only in E. coli strains that contain the pir gene, was regenerated by removing the Tn5 tnp gene (using the SalI restriction enzyme) from the suicide vector pUT.
14 The sacB gene was amplified using PCR from pEX100T 15 and cloned into pGP704 to generate the pSA2000 vector, an E. coli suicide plasmid that carries a negative selectable marker. The two soxS (the WT and the soxS A12S mutant allele) were cloned into this pSA2000 vector to generate two plasmids, pSA2001 and pSA2002, respectively, that were used for the allelic exchange. Plasmids pSA2001 and pSA2002 were introduced into the E. coli JW4023 insertion mutant and those in which the plasmid integrated into the genome via homologous recombination (the first cross-over) were selected as Kn r Ap r resistant colonies. The resulting ampicillin-resistant cells were then grown in the presence of 5% sucrose to force homologous recombination (the second cross-over), which resulted in the loss of the integrated plasmid sequence along with the preexisting soxS::kn sequence, while leaving behind the soxS (WT or soxS A12S ) allele in its place. The mutants that had undergone the proper 
Results

Mutations in the FQ-MDR E. coli isolates
We sequenced soxR, soxS, marR and acrR genes from our E. coli MDR isolates in addition to the entire soxS region to address the possibility that there were other mutations in the soxS gene or its promoter. In all the E. coli isolates that were tested, only a single missense mutation at codon 12 with a G T transversion in codon GCA that changed alanine to serine (Ala-12 Ser) was found. This mutation lies outside the helix-turn-helix motif of the SoxS DNA-binding domain. No mutations were found elsewhere in the soxS gene, soxS promoter or other regulators.
Expression of acrB, soxS and marA in FQ-MDR E. coli isolates
To assess the role of the AcrB pump in contributing to the FQ-MDR phenotype of these isolates, we measured the expression of the genes coding for the pump and its regulators. We determined that basal soxS and acrB were overexpressed (≥2-fold increased expression) in all of the tested E. coli isolates compared with the WT E. coli (CG4468). Upon stimulation with PQ, all the isolates retained the ability to overexpress both soxS and acrB mRNA ( Figures S1 and S2) . In contrast to soxS expression, all of the isolates exhibited low marA expression (0.653 -0.875) (data not shown). This suggests that overexpression of the AcrB efflux pump in those mutants was not due to MarA.
Antibiotic resistance conferred by cloned mutant soxS A12S gene
Because the overexpression of WT soxS can result in enhanced resistance to antibiotics, it was imperative to compare the WT and the mutant soxS A12S allele cloned into the same multicopy plasmid to assess the effect of the mutation. Based on the MIC results, the strain expressing the mutant SoxS protein (DB0003) exhibited at least 2-fold higher basal resistance to ciprofloxacin, enrofloxacin, chloramphenicol and doxycycline compared with the strain expressing the WT SoxS (DB0002). PQ treatment further increased the basal antimicrobial resistance of JW4023 derivatives harbouring either pSAWT or pSAMT, but the strain expressing the mutant SoxS still had higher resistance than the strain expressing the WT SoxS for each antibiotic tested (Figure 1 ). 
Antimicrobial resistance conferred by recombinant mutant soxS allele
To demonstrate that the soxS A12S mutation contributes to the FQ-MDR phenotype, we introduced the mutation into a WT E. coli strain. The E. coli strain harbouring the soxS A12S mutation (SS0002) showed an increase in the basal resistance to enrofloxacin, ciprofloxacin and chloramphenicol compared with the strain harbouring the WT soxS (SS0001). After PQ stimulation, although both the mutant and the WT derivatives showed increased resistance to antibiotics, the soxS A12S mutant had a 2-fold higher MIC of enrofloxacin, doxycycline and chloramphenicol and a 4-fold increase in the MIC of ciprofloxacin compared with the WT (Figure 2) .
Activity of the cloned mutant soxS gene
We determined whether the SoxS A12S mutant protein affected the expression of the target genes. Interestingly, the soxS A12S mutant (SS0002) exhibited an overexpression of acrB without any need for a prior activation of SoxR. Compared with the E. coli strain expressing the WT SoxS (SS0001), the strain expressing the mutant SoxS (SS0002) overexpressed the acrB gene both under nonstressful experimental conditions and after PQ stimulation (Figure 3 ).
Discussion
We previously demonstrated that MDR E. coli experimental isolates harbouring a missense mutation in soxS emerged during soxS mutation contributes to multidrug resistance oral FQ treatment. This was the first report of an soxS mutation in FQ-MDR E. coli isolates. Furthermore, we found the same soxS A12S mutation in clinical FQ-MDR E. coli isolates from infected dogs. Previous studies have identified mutations in soxS, but these mutations were not linked to antimicrobial resistance. 16 In this study, we investigated the possible role of the soxS A12S mutation in contributing to FQ-multidrug resistance in E. coli isolates.
To date, the increased basal expression of soxS in E. coli strains has been assumed to be caused by mutations in the soxR gene that activate the SoxR protein in the absence of oxidative stress. 11, 17 In laboratory experiments, constitutive soxS expression was induced by constructing spacer mutations in the soxS promoter, 18 constitutive mutations affecting the C-terminus of SoxR protein 19 or increasing the half-life of soxS. 20 However, we determined that an increased basal expression of soxS in all the soxS A12S E. coli isolates tested in this study occurred in the absence of any mutation in the soxR gene or the soxS promoter. Additionally, the increased soxS expression was associated with an overexpression of acrB and PQ treatment further increased the expression of both the soxS and acrB genes. These data suggest that the increased resistance of the soxS A12S mutants to several antibiotics might be in part due to an overexpression of the AcrB efflux pump.
In E. coli isolates, increased soxS expression has been associated with a 2-to 4-fold increased resistance to nalidixic acid, chloramphenicol and tetracycline. 11 Here we demonstrated that a trans complementation of soxS deletion in JW4023 with the mutant soxS A12S resulted in an increase in the basal resistance to ciprofloxacin, enrofloxacin, doxycycline and chloramphenicol with or without induction by PQ. Our results were verified when the soxS deletion in JW4023 was complemented in cis with the soxS A12S mutation. In both cases, the E. coli strains expressing the soxS A12S mutation exhibited an increase in the basal antimicrobial resistance to the same tested antimicrobials.
To reveal the mechanism by which the soxS A12S mutation contributes to antimicrobial resistance in E. coli, the expression of the acrB gene was determined in the E. coli strain harbouring the WT soxS (SS0001) and in a strain harbouring the soxS A12S mutation (SS0002). The E. coli strain expressing the mutant SoxS A12S (SS0002) showed an overexpression of acrB mRNA in comparison with the E. coli strain expressing the WT SoxS (SS0001), both under unstressed conditions and after treatment with PQ. Interestingly, the soxS A12S mutants showed an overexpression of acrB without the oxidative stress. This is the first report that directly demonstrates a contribution of the soxS A12S mutation to antibiotic resistance in E. coli. The mechanisms by which this particular mutation catalyses the overexpression of acrB is not yet known. Elucidating such mechanisms will be important for establishing and eventually interfering with the contribution of the soxRS regulon to the emergence of the FQ-MDR phenotype.
